title: Patients' preferences for osteoporosis drug treatment: a discrete choice experiment.
abstract: Active case finding for osteoporosis is used to identify patients at high fracture risk who may benefit from preventive drug treatment. We investigated the relative weight that women place on various aspects of preventive drugs in a discrete choice experiment. Our patients said they were prepared to take preventive drugs even if side effects were expected.
  
  
  BACKGROUND
  Active case finding for osteoporosis is used to identify patients who may benefit from preventive drugs. We aimed to elicit the relative weight that patients place on various aspects of preventive drug treatment for osteoporosis.
  
  
  METHODS
  We designed a discrete choice experiment, in which women had to choose between drug profiles that differed in five treatment attributes: effectiveness, side effects (nausea), total treatment duration, route of drug administration, and out-of-pocket costs. We included 120 women aged 60 years and older, identified by osteoporosis case finding in 34 general practices in the Netherlands. A conditional logit regression model was used to analyse the relative importance of treatment attributes, the trade-offs that women were willing to make between attributes, and their willingness to pay.
  
  
  RESULTS
  All treatment attributes proved to be important for women's choices. A reduction of the relative 10-year risk of hip fracture by 40% or more by the drug was considered to compensate for nausea as a side effect. Women were prepared to pay an out-of-pocket contribution for the currently available drug treatment (bisphosphonate) if the fracture risk reduction was at least 12%.
  
  
  CONCLUSIONS
  Women identified by active osteoporosis case finding stated to be prepared to take preventive drugs, even if side effects were expected and some out-of-pocket contribution was required.
authors.affiliation: Department of Public Health, Erasmus MC-University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. e.debekker@erasmusmc.nl
authors.forename: E W
authors.initials: EW
authors.lastname: de Bekker-Grob
authors.forename: M L
authors.initials: ML
authors.lastname: Essink-Bot
authors.forename: W J
authors.initials: WJ
authors.lastname: Meerding
authors.forename: H A P
authors.initials: HA
authors.lastname: Pols
authors.forename: B W
authors.initials: BW
authors.lastname: Koes
authors.forename: E W
authors.initials: EW
authors.lastname: Steyerberg
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control*; D006620:Hip Fractures / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy* / Q000523:psychology; D010349:Patient Compliance; D017060:Patient Satisfaction; D012307:Risk Factors; D011795:Surveys and Questionnaires
chemical_list: D050071:Bone Density Conservation Agents